Endocyte
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Endocyte sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Endocyte: 18 sponsored US clinical trials, none currently recruiting.
Endocyte sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 16 completed. 1 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 2 trials.
Top-decile sponsor footprint
Endocyte ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
18 total, page 1 of 1
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
NCT03511664
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
NCT03042312
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
NCT03011320
Phase 1 of EC1169 In Patients With Recurrent MCRPC
NCT02202447
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
NCT01999738
Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers
NCT01748864
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
NCT01002924
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
NCT00852189
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
NCT00485563
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors
NCT00441870
Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)
NCT00308269
Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer
NCT00329368
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
NCT01689766
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
NCT01689727
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma
NCT01689662
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
NCT01686256
Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients
NCT01689636
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
NCT00003763
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Therapeutic Areas
How the Endocyte early-phase archive is shaped
18 indexed studies, none listed as recruiting (0% open); 16 completed (89%).
Phase mix: 1 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (2 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Endocyte: archived-pipeline peers nationwide
Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Endocyte sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 archived trials
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Endocyte page
18 registered trials is a research-attention snapshot, not an endorsement of Endocyte or any single study.
- None of Endocyte's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Prostate Cancer is the condition Endocyte studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Endocyte pipeline card: 18 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.